Cargando...

4CPS-160 Use of apremilast in plaque psoriasis as an alternative to biologic treatments

BACKGROUND: Apremilast is a phosphodiesterase4 inhibitor. Two pivotal trials were carried out comparing apremilast to placebo in plaque psoriasis (PP). At week 16, significantly more patients taking apremilast achieved PASI75 (28.8%–33.1%) in both trials, versus placebo (5.3%–5.8%). PURPOSE: To asse...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur J Hosp Pharm
Main Authors: Ruiz, M Pedrosa, Martinez, C Estaun, Moya-Carmona, I
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Group 2018
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535597/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.251
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!